Pioneers in Neuroscience


Driven by our commitment to patients and our passion for neuroscience, Biogen remains focused on furthering Alzheimer’s disease research and treatment. Visit our resource center for the latest information, news and stories about Alzheimer’s disease at Biogen.

2020 Year In Review: Our Commitment to Corporate Responsibility

In an unprecedented year, Biogen continued to accelerate action on key challenges of our time including equity and access, diversity and inclusion and climate and health. Read about our progress on advancing environmental, social and governance (ESG) priorities, and our goals for a healthier, more resilient and equitable future.

Update on Tofersen Clinical Program
How an SMA diagnosis resolved years of unanswered questions

Throughout her life, Marci struggled with basic physical tasks. But when she received an SMA diagnosis at 51 years old, she finally understood the cause of her weak muscles. While SMA is a progressive disease, new innovations can give patients like Marci reasons to hope and a chance for better outcomes.

Biogen updates delivered to your inbox
4/28/21 6:20 PM EDT
Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)
View all news
Diversity, Equity and Inclusion

Biogen is committed to the power of diversity – in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us.

Where Science Meets Humanity

Science that transforms patient lives. Science that seeks to solve societal problems. Science that acts with purpose. Science that is inspired by the diversity and passion of our people. Discover where science meets humanity at Biogen.

Follow us on social media